» Articles » PMID: 23841029

Inhibition of Estrogen-dependent Tumorigenesis by the Thyroid Hormone Receptor β in Xenograft Models

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2013 Jul 11
PMID 23841029
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Association studies suggest that thyroid hormone receptor β (TRβ) could function as a tumor suppressor in breast cancer development, but unequivocal evidence is still lacking. To understand the role of TRβ in breast tumor development, we adopted the gain-of-function approach by stably expressing the THRB gene in a human breast cancer cell line, MCF-7 (MCF-7-TRβ). Parental MCF-7 cells express the estrogen receptor, but not TRs. MCF-7 cells, stably expressing only the selectable marker, the Neo gene, were also generated as control for comparison (MCF-7-Neo cells). Cell-based studies indicate that the estrogen (E2)-dependent growth of MCF-7 cells was inhibited by the expression of TRβ in the presence of the thyroid hormone (T3). In a xenograft mouse model, large tumors rapidly developed after inoculation of MCF-7-Neo cells in athymic mice. In contrast, markedly smaller tumors (98% smaller) were found when MCF-7-TRβ cells were inoculated in athymic mice, indicating that TRβ inhibited the E2-dependent tumor growth of MCF-7 cells. Further detailed molecular analysis showed that TRβ acted to activate apoptosis and decrease proliferation of tumor cells, resulting in inhibition of tumor growth. The TRβ-mediated inhibition of tumor growth was elucidated via down-regulation of the JAK-STAT-cyclin D pathways. This in vivo evidence shows that TRβ could act as a tumor suppressor in breast tumorigenesis. The present study provides new insights into the role of TR in breast cancer.

Citing Articles

GW0742 as a Potential TRα and TRβ Antagonist Reduces the Viability and Metabolic Activity of an Adult Granulosa Tumour Cell Line and Simultaneously Upregulates TRβ Expression.

Gogola-Mruk J, Kumor I, Wojtaszek G, Kulig K, Ptak A Cancers (Basel). 2024; 16(23).

PMID: 39682255 PMC: 11640550. DOI: 10.3390/cancers16234069.


Thyroid Hormone Receptors as Tumor Suppressors in Cancer.

Zhu X, Cheng S Endocrinology. 2024; 165(10).

PMID: 39226152 PMC: 11406550. DOI: 10.1210/endocr/bqae115.


Transcription factor STAT4 counteracts radiotherapy resistance in breast carcinoma cells by activating the MALAT1/miR-21-5p/THRB regulatory network.

Guo L, Ding G, Ba Y, Tan B, Tian L, Wang K Am J Cancer Res. 2024; 14(4):1501-1522.

PMID: 38726265 PMC: 11076251. DOI: 10.62347/VSJU7227.


Hypothyroidism and hyperthyroidism related to gynecologic cancers: a nationwide population-based cohort study.

Leung J, Wang S, Leung H, Yu T, Chan A Sci Rep. 2024; 14(1):1892.

PMID: 38253698 PMC: 10803809. DOI: 10.1038/s41598-023-50439-z.


Triiodothyronine lowers the potential of colorectal cancer stem cells .

Rostkowska O, Olejniczak-Keder A, Spychalski P, Szarynska M, Kobiela J Oncol Rep. 2022; 49(1).

PMID: 36484405 PMC: 9773011. DOI: 10.3892/or.2022.8458.


References
1.
Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N . Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. Ann Surg Oncol. 2010; 17(8):2222-8. DOI: 10.1245/s10434-010-0956-9. View

2.
Tosovic A, Bondeson A, Bondeson L, Ericsson U, Malm J, Manjer J . Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010; 12(3):R33. PMC: 2917028. DOI: 10.1186/bcr2587. View

3.
Ying H, Furuya F, Zhao L, Araki O, West B, Hanover J . Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest. 2006; 116(11):2972-84. PMC: 1592548. DOI: 10.1172/JCI28598. View

4.
Guigon C, Kim D, Willingham M, Cheng S . Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors. Oncogene. 2011; 30(30):3381-90. PMC: 3457781. DOI: 10.1038/onc.2011.50. View

5.
Catalano S, Giordano C, Rizza P, Gu G, Barone I, Bonofiglio D . Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol. 2008; 218(3):490-500. DOI: 10.1002/jcp.21622. View